Valeo Pharma Stock Current Ratio
| VPHIF Stock | USD 0.05 0.00 0.00% |
Valeo Pharma fundamentals help investors to digest information that contributes to Valeo Pharma's financial success or failures. It also enables traders to predict the movement of Valeo Pink Sheet. The fundamental analysis module provides a way to measure Valeo Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Valeo Pharma pink sheet.
Valeo |
Valeo Pharma Company Current Ratio Analysis
Valeo Pharma's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Valeo Pharma Current Ratio | 2.88 X |
Most of Valeo Pharma's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Valeo Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Valeo Pharma has a Current Ratio of 2.88 times. This indicator is about the same for the Healthcare average (which is currently at 2.91) sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current ratio for all United States stocks is 33.33% lower than that of the firm.
Valeo Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Valeo Pharma's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Valeo Pharma could also be used in its relative valuation, which is a method of valuing Valeo Pharma by comparing valuation metrics of similar companies.Valeo Pharma is currently under evaluation in current ratio category among its peers.
Valeo Fundamentals
| Return On Equity | -16.0 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (0.93) % | |||
| Operating Margin | (0.61) % | |||
| Current Valuation | 57.28 M | |||
| Shares Outstanding | 82.19 M | |||
| Shares Owned By Insiders | 47.72 % | |||
| Price To Book | 66.75 X | |||
| Price To Sales | 2.14 X | |||
| Revenue | 27.75 M | |||
| Gross Profit | 8.52 M | |||
| EBITDA | (19.04 M) | |||
| Net Income | (25.75 M) | |||
| Cash And Equivalents | 27.72 M | |||
| Cash Per Share | 0.34 X | |||
| Total Debt | 59.53 M | |||
| Current Ratio | 2.88 X | |||
| Book Value Per Share | (0.22) X | |||
| Cash Flow From Operations | (28.5 M) | |||
| Earnings Per Share | (0.21) X | |||
| Number Of Employees | 115 | |||
| Beta | 2.47 | |||
| Market Capitalization | 35.68 M | |||
| Total Asset | 58.27 M | |||
| Net Asset | 58.27 M |
About Valeo Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Valeo Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Valeo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Valeo Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Valeo Pink Sheet
Valeo Pharma financial ratios help investors to determine whether Valeo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Valeo with respect to the benefits of owning Valeo Pharma security.